Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients

M. Tomirotti, G. Bernardo, C. Epifani, R. Biasioli, R. Franchi, F. Mensi, P. Carnaghi, G. Schieppati, A. Scanni

Research output: Contribution to journalArticlepeer-review

Abstract

Thirty-one patients with metastatic breast cancer not responding or progressing after initial response to adriamycin + cyclophosphamide (AC) treatment entered a phase II study with oral lonidamine in association to AC. Objective clinical responses were observed in 10 patients (32%) and consisted of 1 complete + 9 partial remissions. Disease stability and progression were observed in 8 and 13 cases, respectively. These results were obtained with a marginal toxicity in addition to that already reported for AC therapy, the main additional side effect being myalgia, which was easily manageable in most cases.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalInternational Journal of Oncology
Volume3
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients'. Together they form a unique fingerprint.

Cite this